In consultation: Guidance and quality standards
Showing 1 to 10 of 10
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Topical tapinarof for treating mild to severe plaque psoriasis ID6712 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529] | Draft guidance | Technology appraisal guidance | |
| Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Semaglutide 7.2 mg dose for managing obesity ID6699 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Vamikibart for treating uveitic macular oedema ID6671 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] | Final draft guidance | Technology appraisal guidance | |
| Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610] | Final draft guidance | Technology appraisal guidance |